Construction of clinical comprehensive evaluation index system of anti-lung cancer drugs and empirical study
- VernacularTitle:抗肺癌药品临床综合评价指标体系的构建及实证研究
- Author:
Sisi LIN
1
;
Liping CHEN
2
;
Qiyun JIANG
1
;
Jianwei XUAN
2
;
Qun ZHANG
1
Author Information
1. Office of Drug Clinical Trial Institution，the Third Affiliated Hospital of Southern Medical University，Guangzhou 510630，China
2. Health Economics Research Institute，School of Pharmaceutical Sciences，Sun Yat-Sen University，Guangzhou 510006，China
- Publication Type:Journal Article
- Keywords:
clinical comprehensive evaluation of drugs
- From:
China Pharmacy
2023;34(11):1313-1319
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To construct a comprehensive evaluation index system for anti-lung cancer drugs， and to provide a basis for drug selection and rational clinical use. METHODS Based on the Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs （2021 edition for trial use）， a preliminary evaluation index system framework and an index preselection pool were initially formulated through literature analysis. The evaluation indices were then selected and modified by using the Delphi method. The weights of each index were determined through expert scoring and relevant calculations， thereby establishing a comprehensive evaluation index system for anti-lung cancer drugs. Referred to Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions， scoring detailed rules for clinical comprehensive evaluation indexes of anti-lung cancer drugs were formulated. The constructed comprehensive evaluation index system and scoring detailed rules were applied to conduct empirical evaluation of the anti-lung cancer drug pembrolizumab. RESULTS The constructed comprehensive evaluation index system for anti-lung cancer drugs included 6 primary indicators and 15 secondary indicators. The weights of the primary indicators were as follows： safety （18）， efficacy （38）， economy （15）， innovation （9）， suitability （10）， and accessibility （10）. The scoring detailed rules for the comprehensive evaluation index system for anti-lung cancer drugs had been preliminarily established. The results of empirical evaluation showed that the comprehensive evaluation score （61 points） of pembrolizumab combined with chemotherapy regimen was higher than that of the monotherapy chemotherapy regimen （56 points）. The former demonstrated superior efficacy， innovation and suitability compared to the latter， while the latter exhibited better safety and economy. CONCLUSIONS The constructed comprehensive evaluation index system for anti-lung cancer drugs has the potential for generalizability and practical application， providing a reference basis for rational clinical drug use.
